Archives

by in
Entry Author Date Location
Avalanche Bio Rolls Onto Nasdaq After Upsized, $102M IPO 07/31/14 San Francisco
Stealth Mode is the New Sweet Spot for Some Biotechs 07/14/14 National
East Coast Biotech Roundup: Regeneron, Sarepta, Jounce, & More 07/11/14 Boston
East Coast Biotech Roundup: Vertex, Cubist, Editas, Polaris, & More 06/27/14 Boston
East Coast Biotech Roundup: Bluebird, Moderna, Navitor, & More 06/20/14 Boston
Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study 06/14/14 Boston
East Coast Biotech Roundup: LTI, SolveBio, Proteon, & More 05/16/14 Boston
East Coast Biotech Roundup: Mergers, Rhythm, Regeneron, & More 05/09/14 Boston
AAVLife Gets $12M to Bring Gene Therapy to Rare Ataxia 04/15/14 Boston
Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene Therapy 04/10/14 San Diego
San Diego Life Sciences Roundup: Zogenix, Ignyta, AnaptysBio, & More 03/17/14 San Diego
HIV Treatment Outlook Buoyed by Sangamo Gene Therapy 03/10/14 San Francisco
East Coast Biotech Roundup: VentriNova, RainDance, Biogen, & More 03/07/14 Boston
With Gene Therapy, VentriNova Aims to Mend Broken Hearts 03/04/14 New York
Elliott Sigal, Bristol’s Former R&D Chief, on Life After Big Pharma 02/25/14 New York
East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More 02/14/14 Boston
Third Rock’s Voyager Hunts For CNS Disorders With Gene Therapy 02/12/14 Boston
Gene Therapy Lurches Ahead, Sees Thorny Future Questions on Price 01/27/14 National
What Was Hyped, and What Fell Out of Favor, This Year in Biotech 12/16/13 National
East Coast Biotech Roundup: Juno, Editas, Celgene, & More 12/06/13 Boston
Three VCs Pour $43M Into Editas to “Edit” Out Genetic Disorders 11/25/13 Boston
Moderna Vacuums Up Another $110M to Make Messenger RNA Drugs 11/20/13 Boston
The Biotech Startup Class of 2013: Don’t Worry, It’s a Short List 11/18/13 National
East Coast Biotech Roundup: Vertex, Dimension, Merrimack, & More 11/01/13 Boston
Dimension, Backed by Fidelity, Targets Hemophilia With Gene Therapy 10/31/13 Boston
San Diego Life Sciences Roundup: IPOs, Illumina, KFx Medical, & More 10/17/13 San Diego
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
Audentes, Loaded With $30M, Pursues Gene Therapy for Rare Diseases 07/26/13 San Francisco
Sangamo in Race to Replace Chronic Drug Treatment with Gene Therapies 07/15/13 San Francisco
Trusting Your Partners: A Chat With Celgene’s George Golumbeski 07/11/13 New York
Page 1 of 4 next page »